Senior Director, Immunotherapy, Athenex
Dr. Srivastava is Senior Director, Immunotherapy at Axis Therapeutics leading manufacturing and technical operations of the T cell program. He also serves as Senior Director of Pre-Clinical Operations at Athenex, Inc. He has extensive clinical and translational research experience in the field of adoptive T cell therapies serving both academia and industry. Most recently, he was an Assistant Professor at the Division of Surgical Oncology at the University of Pittsburgh where he led the process development and manufacturing of Tumor Infiltrating Lymphocytes (TIL) to support the multiple adoptive cell therapy Phase II clinical trials. Dr. Srivastava has also served as a Research Investigator at the Bristol Myers Squibb supporting its immuno-oncology discovery program. He received his postdoctoral training at the Surgery Branch, National Cancer Institute and earned his Ph.D. in Immunology at The University of Louisville. He has authored numerous papers including research articles, abstracts, book chapter and expert opinions.